The selective RET inhibitor selpercatinib is safe and effective in both treated and treatment-naïve patients with RET fusion-positive NSCLC.
Outcomes correlate with the number of brain metastases primarily in patients without two actionable molecular targets: epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.
A $4 million National Cancer Institute grant will help Cleveland Clinic mathematical oncologist Jacob Scott, MD, DPhil, study how ecological and evolutionary mechanisms contribute to lung cancer development, progression and drug resistance.
Two analyses of a large Cleveland Clinic cohort confirm the importance of immunotherapy in treating NSCLC brain metastases and reveal critical indicators of efficacy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
These findings confirm a central idea of evolutionary game theory in oncology: we can treat the game, not just the player.
Erlotinib prolongs survival of late-stage non-small cell lung cancer patients with the EGFR mutation. Researchers recently tested whether the drug would improve cure rates when given to early-stage patients.
A study recently published in Lancet Oncology found ALT-803 + nivolumab safe and with early signs of efficacy in patients with mNSCLC considered PD-1-treatment resistant.
Vamsidhar Velcheti, MD, and his team are pursuing novel, targeted therapies for patients with a rare form of NSCLC.